查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602081

皮膚癌診斷與治療藥物市場：依疾病類型和類型分類－2025-2030年全球預測

Skin Cancer Diagnostics & Therapeutics Market by Disease Type (Melanoma, Non-melanoma), Type (Diagnosis, Therapeutics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年皮膚癌診斷和治療市場價值為75.4億美元，預計2024年將達到83.1億美元，複合年成長率為10.43%，到2030年將達到15.1億美元，預計將達到1000萬美元。

皮膚癌診斷和治療藥物市場範圍包括黑色素瘤、基底細胞癌和鱗狀細胞癌等皮膚癌的篩檢、診斷、治療和管理。該領域是由皮膚癌發病率不斷上升、診斷技術的進步以及新型療法的開發所推動的。發病率的上升和人們對皮膚癌風險認知的提高，使得早期檢測和有效治療應用的需求成為首要任務。最終用途主要是醫院、皮膚科診所和研究機構，利用現有技術和尖端技術來改善患者的治療效果。影響成長要素包括診斷影像和分子診斷技術的進步、紫外線照射和老化等因素導致的皮膚癌患者數量的增加，以及對研發的大量投資。新的商機在於個人化醫療方法、人工智慧驅動的診斷工具以及有望提高準確性和功效的聯合治療。鼓勵投資者和公司透過專注於研發合作並擴大與科技公司的策略夥伴關係關係來利用這些趨勢。先進診斷的高成本、監管障礙和不同的地區報銷政策等限制正在挑戰市場的進步。此外，準確診斷不同皮膚癌類型的複雜性需要持續創新和專業知識發展。潛在的創新領域包括開發非侵入性診斷技術、改進的免疫療法以及用於持續監測高風險個體的穿戴式智慧型裝置。該市場競爭激烈且發展迅速，主要參與者都致力於在診斷和治療解決方案方面取得突破。為了保持領先地位，我們必須專注於技術進步，積極應對監管變化，並確保可及性和可負擔性，同時不影響為患者提供的護理品質。

主要市場統計
基準年[2023] 75.4億美元
預測年份 [2024] 83.1億美元
預測年份 [2030] 151.1億美元
複合年成長率（%） 10.43%

市場動態：快速發展的皮膚癌診斷和治療市場的關鍵市場洞察

由於供需的動態互動，皮膚癌診斷和治療藥物市場正在經歷轉型。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 提高全球皮膚癌發生率和認知
    • 政府不斷採取的早期檢測和皮膚癌治療舉措
    • 皮膚癌診斷及治療開發平臺快速成長
  • 市場限制因素
    • 各種皮膚癌治療的高成本
  • 市場機會
    • 皮膚癌診斷與治療藥物的進展
    • 新興國家皮膚癌治療的發展
  • 市場挑戰
    • 皮膚癌放射治療的副作用

波特的五力：開拓皮膚癌診斷和治療藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對皮膚癌診斷和治療藥物市場的影響

外部宏觀環境因素在塑造皮膚癌診斷和治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解皮膚癌診斷和治療藥物市場的競爭狀況

皮膚癌診斷和治療市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣皮膚癌診斷與治療市場供應商的績效評估

FPNV 定位矩陣是評估皮膚癌診斷和治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球皮膚癌發生率和認知不斷提高
      • 加強政府對皮膚癌早期發現和治療的努力
      • 皮膚癌診斷和治療的開發平臺快速成長
    • 抑制因素
      • 各種皮膚癌治療的高成本
    • 機會
      • 皮膚癌診斷與治療藥物研究進展
      • 新興國家皮膚癌治療的發展
    • 任務
      • 皮膚癌放射治療的副作用
  • 市場區隔分析
    • 疾病類型：對惡性黑色素瘤的快速、早期診斷和治療的需求日益成長
    • 類型：改善皮膚癌治療方法的進展以滿足不斷成長的皮膚癌患者數量
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章皮膚癌診斷與治療藥物市場：依疾病類型

  • 惡性黑色素瘤
  • 非黑色素瘤

第7章皮膚癌診斷與治療藥物市場：依類型

  • 診斷
    • 驗血
    • 皮膚鏡檢查
    • 影像檢查
    • 淋巴結活體組織切片
    • 皮膚切片檢查
  • 治療藥物
    • 化療
    • 非侵入性治療
    • 外科手術

第8章北美和南美皮膚癌診斷和治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區皮膚癌診斷與治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲皮膚癌診斷和治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准首個人工智慧驅動的皮膚癌診斷工具
    • Sun Pharma 與 Philogen 合作在歐洲實現皮膚癌治療的商業化
    • Insight 宣布 FDA核准Zynyz (Retifanlimab-Dlwr) 用於治療轉移性/復發性局部進行性默克爾細胞癌 (MCC)

公司名單

  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Elekta AB
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • DermTech, Inc. by Bausch Health Companies Inc.
  • Castle Biosciences, Inc.
  • Veriskin Inc.
  • NeraCare GmbH
  • AB Science
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • bioMerieux SA
  • Sirnaomics, Inc.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • SkylineDx BV
  • Pfizer Inc.
  • DAMAE Medical
  • Novartis AG
  • Amgen, Inc.
  • QIAGEN NV
  • Sun Pharmaceutical Industries Ltd.
  • AMLo Biosciences Ltd.
  • Almirall, SA
  • Sanofi SA
Product Code: MRR-4342CA3266E1

The Skin Cancer Diagnostics & Therapeutics Market was valued at USD 7.54 billion in 2023, expected to reach USD 8.31 billion in 2024, and is projected to grow at a CAGR of 10.43%, to USD 15.11 billion by 2030.

The scope of the skin cancer diagnostics and therapeutics market encompasses the screening, diagnosis, treatment, and management of skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. This field is driven by increasing skin cancer prevalence, advances in diagnostic technologies, and the development of novel therapeutics. The necessity for early detection and effective treatment applications is paramount due to rising incidences and growing awareness about skin cancer risks. End-use is primarily within hospitals, specialized dermatology clinics, and research institutions, leveraging both established and cutting-edge methodologies to improve patient outcomes. Influential growth factors include technological advancements in imaging and molecular diagnostics, the increase in skin cancer cases due to factors like UV exposure and aging populations, and significant investments in research and development. New opportunities lie in personalized medicine approaches, AI-powered diagnostic tools, and combination therapies that promise better precision and effectiveness. Investors and companies are advised to capitalize on these trends by focusing on R&D collaborations and expanding strategic partnerships with technological firms. Limitations such as high costs of advanced diagnostics, regulatory hurdles, and varying reimbursement policies across regions pose challenges for market progression. Furthermore, the complexity of accurately diagnosing different skin cancer types demands continuous innovation and expertise development. Potential areas for innovation include the development of non-invasive diagnostic techniques, improved immunotherapies, and wearable smart devices for continuous monitoring of at-risk individuals. The nature of the market is competitive and rapidly evolving, with key players striving for breakthroughs in both diagnostics and treatment solutions. Staying ahead requires a focus on technological advancements and proactive adaptation to regulatory changes, ensuring accessibility and affordability without compromising on the quality of care offered to patients.

KEY MARKET STATISTICS
Base Year [2023] USD 7.54 billion
Estimated Year [2024] USD 8.31 billion
Forecast Year [2030] USD 15.11 billion
CAGR (%) 10.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Skin Cancer Diagnostics & Therapeutics Market

The Skin Cancer Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Incidences and Rising Awareness of Skin Cancer Globally
    • Rising Government Initiatives for Early Detection and Skin Cancer Treatment
    • Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
  • Market Restraints
    • High Cost Associated With the Various Skin Cancer Treatment
  • Market Opportunities
    • Advancements in Skin Cancer Diagnostics & Therapeutics
    • Developments of Skin Cancer Care in Emerging Nations
  • Market Challenges
    • Side Effects of Radiation Therapy for Skin Cancer

Porter's Five Forces: A Strategic Tool for Navigating the Skin Cancer Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Skin Cancer Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Skin Cancer Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Skin Cancer Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Skin Cancer Diagnostics & Therapeutics Market

A detailed market share analysis in the Skin Cancer Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Skin Cancer Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Skin Cancer Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Skin Cancer Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include F. Hoffmann-La Roche AG, Abbott Laboratories, Agilent Technologies, Inc., Elekta AB, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, DermTech, Inc. by Bausch Health Companies Inc., Castle Biosciences, Inc., Veriskin Inc., NeraCare GmbH, AB Science, Eli Lilly and Company, GlaxoSmithKline PLC, bioMerieux SA, Sirnaomics, Inc., Merck & Co., Inc., AstraZeneca PLC, SkylineDx BV, Pfizer Inc., DAMAE Medical, Novartis AG, Amgen, Inc., QIAGEN N.V., Sun Pharmaceutical Industries Ltd., AMLo Biosciences Ltd., Almirall, S.A., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Skin Cancer Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Melanoma and Non-melanoma.
  • Based on Type, market is studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy. The Therapeutics is further studied across Chemotherapy, Non-invasive Therapy, and Surgery.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidences and Rising Awareness of Skin Cancer Globally
      • 5.1.1.2. Rising Government Initiatives for Early Detection and Skin Cancer Treatment
      • 5.1.1.3. Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost Associated With the Various Skin Cancer Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Skin Cancer Diagnostics & Therapeutics
      • 5.1.3.2. Developments of Skin Cancer Care in Emerging Nations
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects of Radiation Therapy for Skin Cancer
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas
    • 5.2.2. Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Melanoma
  • 6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
    • 7.2.1. Blood Tests
    • 7.2.2. Dermatoscopy
    • 7.2.3. Imaging Tests
    • 7.2.4. Lymph Node Biopsy
    • 7.2.5. Skin Biopsy
  • 7.3. Therapeutics
    • 7.3.1. Chemotherapy
    • 7.3.2. Non-invasive Therapy
    • 7.3.3. Surgery

8. Americas Skin Cancer Diagnostics & Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
    • 11.3.2. Sun Pharma, Philogen Collaborate to Commercialise Skin Cancer Drug in Europe
    • 11.3.3. Incyte Announces FDA Approval Of Zynyz (Retifanlimab-Dlwr) For Treatment Of Metastatic/Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

Companies Mentioned

  • 1. F. Hoffmann-La Roche AG
  • 2. Abbott Laboratories
  • 3. Agilent Technologies, Inc.
  • 4. Elekta AB
  • 5. Bristol-Myers Squibb Company
  • 6. Daiichi Sankyo Company, Limited
  • 7. DermTech, Inc. by Bausch Health Companies Inc.
  • 8. Castle Biosciences, Inc.
  • 9. Veriskin Inc.
  • 10. NeraCare GmbH
  • 11. AB Science
  • 12. Eli Lilly and Company
  • 13. GlaxoSmithKline PLC
  • 14. bioMerieux SA
  • 15. Sirnaomics, Inc.
  • 16. Merck & Co., Inc.
  • 17. AstraZeneca PLC
  • 18. SkylineDx BV
  • 19. Pfizer Inc.
  • 20. DAMAE Medical
  • 21. Novartis AG
  • 22. Amgen, Inc.
  • 23. QIAGEN N.V.
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. AMLo Biosciences Ltd.
  • 26. Almirall, S.A.
  • 27. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023